Share Name Share Symbol Market Type Share ISIN Share Description
Horizon Discvry LSE:HZD London Ordinary Share GB00BK8FL363 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.50p +1.27% 120.00p 118.00p 122.00p 120.50p 118.50p 118.50p 181,071.00 16:01:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 20.2 -10.5 -11.2 - 114.28

Horizon Discvry (HZD) Latest News

More Horizon Discvry News
Horizon Discvry Takeover Rumours

Horizon Discvry (HZD) Share Charts

1 Year Horizon Discvry Chart

1 Year Horizon Discvry Chart

1 Month Horizon Discvry Chart

1 Month Horizon Discvry Chart

Intraday Horizon Discvry Chart

Intraday Horizon Discvry Chart

Horizon Discvry (HZD) Discussions and Chat

Horizon Discvry Forums and Chat

Date Time Title Posts
05/12/201608:21Horizon Discovery Ltd - Genomic translation 625.00
23/7/201414:43Alan Green says to BUY and HOLD in Horizon-

Add a New Thread

Horizon Discvry (HZD) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:15:06120.00260,000312,000.00O
16:36:25120.0010,00012,000.00O
16:06:24120.0020,00024,000.00O
15:53:08120.50414498.87O
14:48:00120.50405488.03O
View all Horizon Discvry trades in real-time

Horizon Discvry (HZD) Top Chat Posts

DateSubject
05/12/2016
08:20
Horizon Discvry Daily Update: Horizon Discvry is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker HZD. The last closing price for Horizon Discvry was 118.50p.
Horizon Discvry has a 4 week average price of 124.50p and a 12 week average price of 138.38p.
The 1 year high share price is 187p while the 1 year low share price is currently 105p.
There are currently 95,232,459 shares in issue and the average daily traded volume is 444,127 shares. The market capitalisation of Horizon Discvry is £114,278,950.80.
29/11/2016
12:53
mamcw: I agree the lack of revenue transparency in the recent RNSs is frustrating. In these potential high growth situations, you are ultimately betting on the CEO to deliver. Julian Dunkerton did at Supergroup; I have a feeling Jim Mullen will do so at Ladbroke Coral Group and I'm betting on DD to do the same here, despite the dreadful share price performance . But then I like my glass half full :)
29/11/2016
10:54
deltrotter: Thanks Kestelmill. He certainly hasn't anything to shout about at the moment! Still, I am a patient investor and it is what the share price is in 2021 rather than now that matters to me.
28/11/2016
12:30
kestelmill: I was on a long train journey on Friday so used the time to have a good look at all the reports and interims of HZD to work out what is going on here. These are my conclusions and thoughts. 1) The last interim gave revenue guidance of £24-26M but also said that revenues would be reduced by £2.7M in 2016 due to restructuring. This was effectively a profit warning - analysts were expecting more like £27-29M revenue and associated profit (loss) - and that is why the share price went down so much. 2) There is a restructuring process and an initiative to make £5M cost savings (£3M from closing down Boston). There is significant execution risk attached to this. 3) CEO has stated EBITDA will be positive in 2017. This reads as, EBITDA will be more than £0, but not by much. Analysts may well have been expecting more. 4) Even if positive EBITDA is achieved, there was £7.4M depreciation and amortisation in 2015. We can expect similar or higher figures every year for many years to come. This means HZD has to make >£8M EBITDA to truly break even on their P+L. Note there are £48M of Goodwill and intangible assets currently on the balance sheet; it looks like they are amortising over 10 years. 5) HZD has a strong technology licence position in gene editing but since the environment and, in particular, Crispr technology is still evolving and has an unclear IP situation, they may have to invest further in the future to protect their position. Also, they may have to, or decide to (since they are acquisitive), do further acquistions. This would create further complexity/risk. 6) There are clear current issues with service revenues. The stream of RNS telling us they have new business is reassuring - but these cannot be material to the revenue situation or they would have said so in the RNS. The company makes £20M revenues so you would expect some wins in the course of their ordinary business. On the other hand: a) they should be cash generative from 2017 b) these are growing markets and technologies which are yet to be fully realised c) they are very well positioned in gene editing and NGS d) there are potential additional upsides in the shape of Avvinity and the £200M+ of future royalties (although I am not putting any value on these at present) If HZD can grow revenues 25% for the next 3 years they will easily justify their current valuation. I believe they can do this so my overall conclusion is that this remains a good investment at the current share price
24/11/2016
11:40
kestelmill: What more could they do on IR? They are posting good news every 5 mins. Hopefully it is simply that the IIs have decided they can't wait for HZD and have decided to get out, depressing the share price. I guess we will find out if something is afoot in due course.
16/11/2016
17:04
mamcw: Yup ... and the share price resumes its downward trend. All very dispiriting for an investor (and management, I suspect).
15/11/2016
15:41
kestelmill: Don't forget this share price should have been going up due to exchange rate benefits, having most sales in EUR and USD and repatriating to GBP. So actual share price performance has been even worse than it looks. You could be excused for wondering if some bad stuff is going on at the company that people like us aren't aware of. But actually the share price went down sharply on the latest report that service revenue had stalled and the company was still loss-making. I still believe the company is a decent product play and the service revenue issue could be a blip due to moving some of the capabilities to Cambridge from USA. Anyone close to the company got any insights?
10/11/2016
11:27
kestelmill: HZD releases favourable news all the time, so we may have to wait a while for the market to love this stock. However, if the results are good the share price will rise. I believe HZD have a very compelling offering in a number of areas, not least NGS standards, and that the revenues will follow, and with it the rise in share price. Also as a startup that has grown rapidly there is no doubt loads of fat in this business that can be stripped out.
10/11/2016
10:15
pjj71: not even the mega rally in US BIO has changed the share price fortunes!!! Come on HZD
20/10/2016
14:13
kestelmill: Yes, amazing how people get into a panic as the share price is going down and there hasn't been any news for 5 mins. What's important is that the fundamentals are there, i.e. good demand being met at a good gross margin, a strong competitive advantage and barriers to entry. I will also be adding at this price and hopefully even lower. The only concern for me is that the services revenues have stalled. I wasn't expecting this. However, the products revenues is increasing very nicely. The other thing to point out is that the CEO is clearly highly entrepreneurial and starting lots of different projects, only some of which will be successful. At this stage of a business there is likely to be fat and unprofitable areas in the business as they give things a go and see what works. In 5 years time they may have a different CEO or perhaps Private Equity buy-out which will focus in and strip out any excess.
14/9/2016
07:35
nurdin: 'Horizon Discovery Group PLC with EPIC/TICKER LON:HZD has had its stock rating noted as ‘Retains’; with the recommendation being set at ‘BUY’ this morning by analysts at Panmure Gordon. Horizon Discovery Group PLC are listed in the Health Care sector within AIM. Panmure Gordon have set a target price of 270 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 62.7% from the opening price of 166 GBX. Over the last 30 and 90 trading days the company share price has increased 13 points and increased 15.25 points respectively.' Nice.
Horizon Discvry share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:34 V: D:20161205 20:44:37